글로벌 과민성 방광 치료 시장 – 2029년까지의 산업 동향 및 예측

과민성 방광 치료 시장의 시장 분석 및 통찰력

Data Bridge Market Research는 과활성 방광 치료 시장이 2022-2029년 예측 기간 동안 약 4.00%의 CAGR을 보일 것이라고 분석했습니다. 신장 관련 질환 의 유병률 증가, 의료 기기 와 관련된 연구 개발 능력에 대한 집중 증가 , 첨단 IT 의료 기술 도입 , 전 세계적으로 노인 인구 기반 증가, 특히 개발 도상국에서 의료 인프라 개발에 대한 지출 증가가 과활성 방광 치료 시장 성장에 기여하는 주요 요인입니다.

이름 자체에서 알 수 있듯이 과활성 방광은 환자가 소변을 자주 보고 싶어하는 충동과 때때로 소변 누출이 함께 나타나는 의학적 장애를 말합니다. 과활성 방광은 배뇨 빈도를 거의 8배 증가시킵니다. 따라서 과활성 방광 치료는 이 문제로 고통받는 환자에게 제공됩니다.   

목표 연구 활동 에 대한 공공-민간 자금 지원의 급증은   시장 성장을 촉진하는 주요 요인 중 하나입니다. 파킨슨병 및  당뇨병 과 같은 만성 질환의 유병률 증가는 또 다른 시장 성장 결정 요인입니다. 끊임없이 증가하는 새로운 도구의 기술적 발전 및 혁신, 급증하는  약물  발견 활동 수, 외인성 마커의 새로운 구성 요소 도입 증가, 정부 자금 지원 증가 및 신흥 시장의 미개척 잠재력은 수익성 있는 시장 성장 기회를 더욱 창출할 것입니다.

그러나 현재의 과활성 방광 치료의 원치 않는 전신적 효과와 평가 중 약물의 부작용은 시장 성장률을 탈선시킬 것입니다. 또한, 숙련된 의료 전문가의 부족, 과활성 방광의 유병률에 대한 인식 부족, 개발도상국과 저개발 경제권에서 유리한 환불 시나리오의 부족은 시장에 더 큰 과제를 안겨줄 것입니다.

This overactive bladder treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on overactive bladder treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Overactive Bladder Treatment Market Scope and Market Size

The overactive bladder treatment market is segmented on the basis of pharmacotherapy and disease type. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• Based on pharmacotherapy, the overactive bladder treatment market is segmented into anticholinergics, solifenacin, oxybutynin, darifenacin, fesoterodine, tolterodine, trospium, and others.
• Based on disease type, the overactive bladder treatment market is segmented into idiopathic bladder overactivity and neurogenic bladder overactivity. The neurogenic bladder overactivity segment is sub-segmented into Parkinson's disease, stroke, multiple sclerosis, spinal cord injury and other disorders.

Overactive Bladder Treatment Market Country Level Analysis

The overactive bladder treatment market is analysed and market size insights and trends are provided by country, pharmacotherapy and disease type as referenced above.

The countries covered in the overactive bladder treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the overactive bladder treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is because of the increase in the expenditure for research and development proficiencies and availability of multiple health care systems such as Medicare. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period owing to the increasing government expenditure on healthcare sector, ever-rising geriatric population base, and rising personal disposable income.

The country section of the overactive bladder treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The overactive bladder treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for overactive bladder treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the overactive bladder treatment market. The data is available for historic period 2010 to 2020.

Competitive Landscape and Overactive Bladder Treatment Market Share Analysis

The overactive bladder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to overactive bladder treatment market.

과민성 방광 치료 시장 보고서에서 활동하는 주요 기업으로는 Astellas Pharma Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Allergan, Endo International plc, Hisamitsu Pharmaceutical Co.,Inc., Sanofi, Aurobindo Pharma., Johnson & Johnson Services, Inc., Intas Pharmaceuticals Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., Medtronic, Laborie, Inc., Thermo Fisher Scientific Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN, Bio-Rad Laboratories, Inc., Hologic, Inc. 등이 있습니다.

SKU-19330